← Eichor
Study identifier: NCT07572903 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease

Condition: Parkinson s Disease  ·  Sponsor: The First Affiliated Hospital of Anhui Medical University

PhaseNA
Planned participants90
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

This study aimed to observe the clinical efficacy and safety of single-target transcranial temporal stimulation (tTIS) intervention in Parkinson's disease (PD) patients and explore the neurophysiological mechanism of TIS intervention. The study was designed as a three-arm (A: GPi group, B: STN group, C: Sham group), randomized, double-blind, parallel-controlled trial. PD patients in the drug-off state (≥12 hours after drug withdrawal) were randomly assigned to receive either tTIS or sham stimulation targeting GPi/STN, with each stimulation lasting 30 minutes. Clinical symptom assessments were conducted before and after the intervention, and safety was monitored by researchers throughout the process.

This description comes directly from the study's public registry record.

Talk to the study team

Junjun Wu  ·  +86 0551 62923704  ·  2445011385@stu.ahmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Anhui Medical UniversityHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07572903